Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hangzhou Gallop Biological Products is a Chinese biotechnology company specializing in the development and manufacture of therapeutic biological products, particularly antivenoms and antitoxins. The company is a leading provider of treatments for venomous bites from various snake species, including cobras, vipers, and kraits, as well as spider bites. Their product portfolio includes purified polyclonal antibodies derived from equine plasma, designed to neutralize specific toxins. Hangzhou Gallop operates large-scale manufacturing facilities that adhere to Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of their life-saving treatments. The company serves both domestic and international markets, playing a critical role in emergency medicine and public health.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hangzhou Gallop Biological Products.